CSIMarket Company Name, Ticker, Customers, else..
 
Instil Bio Inc   (NASDAQ: TIL)
 
Price: $7.5800 $-0.08 -1.044%
Day's High: $7.639999866485596 Week Perf: -0.39 %
Day's Low: $ 7.58 30 Day Perf: 4.12 %
Volume (M): 2,747 52 Wk High: $ 30.50
Volume (M$): $ 0 52 Wk Avg: $10.56
Open: $7.59 52 Wk Low: $5.67



 Market Capitalization (Millions $) 51
 Shares Outstanding (Millions) 7
 Employees 17
 Revenues (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -30
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Business Description


Instil Bio Inc is a biotechnology company that focuses on developing innovative cell and gene therapies for the treatment of cancer. The company is committed to utilizing cutting-edge technologies to engineer and modify immune cells to enhance their ability to recognize and destroy cancer cells. Instil Bio aims to transform the treatment landscape for cancer patients by offering personalized and effective therapies that harness the power of the immune system.


   Company Address: 3963 Maple Avenue, Suite 350 Dallas 75219 TX
   Company Phone Number: 499-3350   Stock Exchange / Ticker: NASDAQ TIL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
FATE        2.06% 
IBRX        0.37% 
IVVD   -14.4%    
LENZ        16.63% 
MRNA        5.48% 
SNTI   -11.78%    
• View Complete Report
   



Clinical Study

Pioneering Advances in Immunotherapy Instil Bios Breakthrough in Squamous NSCLC Treatment

Published Wed, Sep 10 2025 11:56 AM UTC

In the dynamic landscape of oncological treatments, the recent developments by Instil Bio Inc. in the realm of immune oncology have sparked interest within the scientific community. The company’s announcement of the positive clinical results surrounding their novel 2510 monotherapy for patients with second-line and beyond squamous non-small cell lung cancer (NSCLC) was unv...
Product Service News

Dual Targeting Instil Bio and ImmuneOnco Chart a New Course with SYN-2510/IMM2510 in Cancer Treatment

Published Mon, Sep 16 2024 10:00 AM UTC

In a significant step forward in oncology, Instil Bio, Inc. (Nasdaq: TIL) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX:1541) have unveiled an ambitious global registrational strategy for their innovative PD-L1xVEGF bispecific antibody, SYN-2510/IMM2510. This development is particularly noteworthy as the drug is being positioned as a front-line treatment for two of...
Licensing Agreement

Triple Threat Instil Bio and ImmuneOnco Unite for Next-Generation Cancer Immunotherapy

Published Thu, Aug 1 2024 10:00 AM UTC

In an industry-defining collaboration, Instil Bio, Inc. (Nasdaq: TIL, Instil) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, ImmuneOnco) have announced a landmark agreement focusing on innovative immunotherapy solutions. The pivotal development saw Instil obtaining exclusive ex-China development and commercial rights to ImmuneOnco’s pioneering PD-L1...
Management Announcement

Instil Bio: Overcoming Financial Challenges and Paving the Way for Cancer Therapies

Published Tue, Jan 16 2024 1:01 PM UTC


In exciting news in the field of biopharmaceuticals, Instil Bio, Inc. recently released a strategic update, outlining their path forward in developing revolutionary tumor infiltrating lymphocyte (TIL) therapies for patients battling cancer. The company, listed on NASDAQ as TIL, has been dedicated to finding innovative solutions for cancer treatment, but has faced signif...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 5.73
Price to Sales (Expected) -
Price to Book 0.48
PEG (TTM) -

Financial Strength Current
Quick Ratio 21.08
Working Capital Ratio 24.1
Leverage Ratio (MRQ) 0.84
Total Debt to Equity 0.79
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -4.49 $
Revenues (TTM) 1.32 $
Cash Flow (TTM) -
Cash 10.27 $
Book Value 15.83 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 527,529
Net Income per Employee (TTM) -1,781,235
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.04

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -248.93 %
Net Margin (MRQ) -191.75 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Instil Bio Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.